These reports contribute to the data that drives regulatory action and helps protect others
Semaglutide topped AstraZenecas weekly GLP-1, Bydureon, and Merck & Co.s Januvia, a DPP-4 med and fellow incretin mimetic, in two separate studies in Type 2 diabetes
9% of patients discontinued treatment in semaglutide arm due to AEs
On the clinical side, cost remains the main access barrier
Jun HJ, Ok S, Tyler R, Hwang SY, Chae S
During your discovery call and consultation, we will review your goals, discuss testing and treatment options, and clearly explain pricing before you begin